Compare IDEXX Laboratories, Inc. (IDXX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M). The key difference: IDEXX Laboratories, Inc. is far larger — about 111.1× YieldMax Universe Fund of Option Income ETFs's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 1,181,378). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| IDXX | YMAX | |
|---|---|---|
Market Cap | $40.43B | $364M |
Volume | 692,164 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $12.70 |
52-Week Low | $504.70 | $7.27 |
Typical Hold Time | 46 Days | 56 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
YMAX trades at $7.48, down 0.66% with a bearish technical outlook showing 18 sell signals versus 2 buy signals. The ETF faces fundamental challenges with declining NAV and concerns about distribution sustainability despite offering high yields. Recent news highlights weekly dividend distributions but also raises questions about the fund's structure and cost efficiency.
The outlook remains cautious due to persistent NAV erosion and structural concerns. While the high distribution yield attracts income investors, the fund's declining share price and potential for reverse splits present significant risks. Investors should weigh the attractive income against the potential for principal erosion in this complex ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
